(RUBY) – PRNewswire
-
Senda Biosciences Announces Close of $123 Million Series C Financing
-
HotSpot Therapeutics Appoints Jose Carmona to Board of Directors
-
Flagship Pioneering Bolsters Executive Team with Appointment of Michelle C. Werner as CEO-Partner and CEO of Alltrna
-
Flagship Pioneering Announces Appointment of Margo Georgiadis as CEO-Partner
-
Flagship Pioneering Named to Fast Company's Annual List of the World's Most Innovative Companies for 2022
-
Alltrna Appoints Rare Disease Clinical Research Expert, Dr. Anne Pariser, as Vice President, Medical and Regulatory Affairs
-
INVAIO SCIENCES STRENGTHENS ITS BOARD OF DIRECTORS WITH THE APPOINTMENT OF HUGH GRANT
-
Senda Biosciences Appoints Stuart Milstein, Ph.D., as SVP and Head of Platform Biology
-
Flagship Pioneering Announces Appointment of Tom DiLenge as Senior Partner, Global Public Policy, Regulatory & Governmental Strategy
-
Flagship Pioneering Announces Appointment of Justine Levin-Allerhand as Senior Partner, Corporate Development
-
Flagship Pioneering Launches Alltrna to Unlock Transfer RNA Biology and Treat Thousands of Diseases with a Single tRNA Medicine
-
Pioneering Medicines, An Initiative Of Flagship Pioneering, Establishes First-Of-Its-Kind Partnership With The Cystic Fibrosis Foundation To Develop Breakthrough Treatments For CF
-
Invaio Sciences Secures $50 Million Debt Financing to Develop and Commercialize Agricultural Solutions to Address Climate Change
-
Laronde Attracts $440M in First External Financing to Further Advance Endless RNA™ Platform
-
Dr. Stephen Hahn, 24th US FDA Commissioner and Former Chief Medical Executive at MD Anderson, joins Flagship Pioneering as Chief Medical Officer of Flagship's Preemptive Medicine and Health Security I
-
Flagship Pioneering Closes $3.4 Billion Capital Pool to Drive Continued Breakthrough Innovations in Human Health and Sustainability
-
Senda Biosciences Announces Closing of $98 Million Series B Financing
-
Invaio Sciences Raises $88.9 Million to Accelerate the Transition to Biological Agriculture
-
Invaio Sciences Announces Key Agreement with Fundecitrus in Brazil to Combat Against Citrus Greening
-
Invaio Sciences Strengthens Leadership Team with Appointment of Peleg Chevion as President and Chief Commercial Officer
-
Cellarity Raises $123 Million in Series B Funding to Pioneer a New Approach to Drug Discovery, Treating Disease at the Level of the Cell as Opposed to a Single Molecular Target
-
Flagship Pioneering Unveils Pioneering Medicines
-
Flagship Pioneering Announces Appointment of Dr. Luciano Rossetti as New Chief Medical Officer
-
Flagship Pioneering Unveils Senda Biosciences to pioneer Intersystems Biology and create novel treatments for human disease
-
Flagship Pioneering Strengthens Leadership with Appointment of Christine Heenan as Senior Partner and Chief Communications Officer
-
Flagship Pioneering Announces Appointment of Tuyen Ong as CEO-Partner
-
Flagship Pioneering Announces Valo Health to Transform Drug Development
-
Flagship Pioneering's Scientists Invent Machine Learning-Powered Platform to Generate Novel Biomedicines
-
Flagship Pioneering Expands Executive Team with Appointment of Guillaume Pfefer as CEO-Partner
-
Flagship Pioneering's Scientists Invent a New Category of Genome Engineering Technology: Gene Writing
-
Flagship Pioneering Bolsters Executive Team with Appointment of Fabrice Chouraqui in Newly Created Dual Role of Flagship CEO-Partner and CEO of Cellarity
-
Flagship Pioneering Unveils Latest Company: Invaio Sciences
-
Flagship Pioneering Completes Raising a New $1.1 Billion Capital Pool
-
Flagship Pioneering Announces Ohana Biosciences
-
Flagship Unveils Newest Pioneering Platform: Ring Therapeutics
-
Flagship Pioneering Strengthens Leadership With Appointment of Paul Biondi as Executive Partner
-
Flagship Pioneering Unveils Cellarity, the First Company to Discover Medicines Targeting Cell Behavior
-
Flagship Pioneering Names Dr. Nancy Simonian, CEO of Syros, as Recipient of the 2019 Pioneering Leader Award
-
Torque Presents Preclinical Data for Lead Deep-Primed Cellular Immunotherapy Programs at AACR 2019 Special Conference on Tumor Immunology and Immunotherapy
-
Flagship Pioneering Appoints Prakash Raman, Ph.D. as Senior Partner and Chief Business Development Officer
-
Torque Presents New Preclinical Data for Three Deep-Primed Cellular Immunotherapy Programs, Including Newly Unveiled Deep TLR, at SITC 2019 Meeting
-
Entrada Therapeutics Appoints Nathan Dowden as Chief Operating Officer
-
Flagship Pioneering Unveils Cygnal Therapeutics
Back to RUBY Stock Lookup
